Date: 2018-07-10
Type of information: Development agreement
Compound: five mRNA therapeutic programs for rare diseases with high unmet
medical need
Company: BioNTech (Germany) Genevant Sciences (USA - MA)
Therapeutic area: Rare diseases - Genetic diseases
Type agreement: development - commercialisation
Action mechanism: mRNA
Disease: Rare diseases
Details:
- • On July 10th, 2018, BioNTech AG and Genevant Sciences announced that they have entered into a collaboration to develop five mRNA therapeutic programs for rare diseases with high unmet medical need. The companies have also agreed a series of exclusive licenses covering the application of Genevant’s delivery technology to five of BioNTech’s oncology programs.
- The collaboration in rare diseases will combine Genevant’s industry-leading lipid nanoparticle (LNP) delivery technology with BioNTech’s cutting-edge mRNA drug discovery platform to develop best-in-class therapeutics. Both companies have established GMP-grade manufacturing capabilities and infrastructure.
- Under the terms of the agreement, Genevant and BioNTech will pursue the co-development and co-commercialization of five mRNA programs. Genevant and BioNTech will share all future costs and profits for these programs on a 50/50 basis. The companies aim to initiate clinical development in 2020.
Financial terms:
- Genevant is eligible to receive significant commercial milestones for the oncology licenses.
Latest news:
Is general: Yes